Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771626 · ClinicalTrials.gov registry record · Phase 1
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT02771626 is a Phase 1 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 118 participants.
The verdict
NCT02771626, a Phase 1 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
Interventions
- DRUG Nivolumab
- DRUG CB-839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2020-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02771626
The ClinicalTrials.gov registry entry for NCT02771626 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02771626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02771626 about?
NCT02771626 is a clinical study titled "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)". This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
What is the current status of trial NCT02771626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2016-08-01. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT02771626?
The interventions under investigation include: Nivolumab (DRUG), CB-839 (DRUG).
Who is sponsoring clinical trial NCT02771626?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.